SCHEMBL770365

SCHEMBL770365

O=C(NCC(=O)N1CCC2CCCC=C2C1)Nc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
TP53 P04637 2/20 0.44
EPHX2 P34913 1/20 0.43
EPHX1 P07099 1/20 0.43
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 2/20 0.40
YAP1 P46937 1/20 0.40
TEAD4 Q15561 1/20 0.40
ALDH1A1 P00352 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 1/20 0.38
STAT1 P42224 1/20 0.38
FAAH O00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770460 0.89 EPHX2 (0.45) NPC1RAB9AEPHX2EPHX1KMT2A
SCHEMBL770993 0.86 PPID (0.48) EPHX1MEN1KMT2ANPSR1
SCHEMBL771012 0.83 GAA (0.46) SMN1; SMN2NPC1RAB9ATP53MEN1
SCHEMBL771027 0.82 PPID (0.35) SMN1; SMN2MEN1POLBKMT2ATSHR
SCHEMBL770227 0.81 LMNA (0.34) SMN1; SMN2POLBKMT2AALDH1A1MAPT
SCHEMBL772126 0.80 ALDH1A1 (0.36) RAB9AMEN1POLBKMT2ATSHR
SCHEMBL771006 0.80 EPHX1 (0.46) SMN1; SMN2NPC1RAB9ATP53EPHX2
SCHEMBL15380799 0.80 EPHX1 (0.46) SMN1; SMN2NPC1RAB9ATP53EPHX2
SCHEMBL770013 0.79 ALDH1A1 (0.43) SMN1; SMN2NPC1RAB9ATP53MEN1
SCHEMBL770629 0.79 TACR1 (0.38) SMN1; SMN2MEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 BRD4 2923/4885SMN1; SMN2 3653/4885NPC1 97/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 BRD4 2959/4885SMN1; SMN2 3637/4885NPC1 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.